For the Inventor, By the Inventor

Enter assignee name

Basel, Switzerland

Axovant Sciences Gmbh

USPTO Granted Patents = 8

% Expired Patents = 62.5

EPO Patents = 2

Forward Citations = 16

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Andrew Cook (3 out of 22 patents)

Lawrence Tim Friedhoff (3 out of 5 patents)

Shankar Ramaswamy (3 out of 3 patents)

4. Yandong Wen (3 out of 3 patents)

5. Andrew J McRiner (3 out of 18 patents)

6. Duane A Burnett (3 out of 63 patents)

7. Raksha A Acharya (3 out of 10 patents)

8. Matthew Gregory Bursavich (3 out of 25 patents)

9. Bryce Alden Harrison (3 out of 21 patents)

10. Tsu Tshen Chuang (2 out of 2 patents)

11. Ann Jacqueline Hunter (2 out of 2 patents)

12. David John Virley (2 out of 2 patents)

13. Gerhard Koenig (1 out of 6 patents)

14. Richard Chesworth (107 patents)

15. Gideon Shapiro (75 patents)

8 patents: Sort by Forward Citations

1. 11304932 - Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HTserotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease (2022-04-19),

2. 10428062 - Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors (2019-10-01),

3. 10370370 - Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors (2019-08-06),

4. 10183938 - Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors (2019-01-22),

5. 10034859 - Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease (2018-07-31),

6. 10022355 - Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder (2018-07-17),

7. 9808455 - Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline (2017-11-07),

8. 9084742 - Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline (2015-07-21),

Company Overview

Axovant Sciences GmbH is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for treating neurological disorders. The company is committed to developing and commercializing novel gene therapies and small molecule drugs to address unmet medical needs in areas such as Parkinson's disease and dementia.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

8 Patents

#46 in Basel

#1,221 in Switzerland

Basel, Switzerland

Axovant Sciences Gmbh

Forward Citations = 16

13 inventors:

Andrew Cook (3 out of 22 patents)

Lawrence Tim Friedhoff (3 out of 5 patents)

Shankar Ramaswamy (3 out of 3 patents)

4. Yandong Wen (3 out of 3 patents)

5. Andrew J McRiner (3 out of 18 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Axovant Sciences Gmbh. Retrieved from https://idiyas.com/company/axovant-sciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…